Akorn, Inc. Announces Fourth Quarter 2012 Earnings Release And Conference Call Information

Tue Feb 5, 2013 4:04pm EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130205:nPnCL54951


LAKE FOREST, Ill., Feb. 5, 2013 /PRNewswire/ -- Akorn, Inc. (NASDAQ: AKRX) will
host a conference call on  Tuesday, February 26, 2013, to discuss fourth quarter
and year-end 2012 results followed by a Q&A session.  The company will release
earnings the same day before the market opens.

 Subject:                Akorn, Inc. Fourth Quarter 2012 Conference Call         
 Date/Time:              Tuesday, February 26, 2013, at 10:00 a.m. Eastern Time  
 Domestic Callers:       888-438-5448                                            
 International Callers:  719-785-1753                                            
 Confirmation Code:      3343969                                                 
 URL For Webcast:        http://www.videonewswire.com/event.asp?id=92105         


http://www.videonewswire.com/event.asp?id=92105

A live broadcast of Akorn's conference call will also be available online at 
www.akorn.com  under the Investor Relations tab on  February 26, 2013, beginning
at  10:00 a.m. (Eastern Time).  The online replay will follow immediately and
will be available for 30 days.   

About Akorn, Inc.

Akorn, Inc. is a niche pharmaceutical company engaged in the development,
manufacture and marketing of multisource and branded pharmaceuticals.  Akorn has
manufacturing facilities located in  Decatur, Illinois;  Somerset, New Jersey 
and Paonta Sahib,  India  where the Company manufactures sterile ophthalmic and
injectable pharmaceuticals.  Additional information is available on the
Company's website at  www.akorn.com.

SOURCE  Akorn, Inc.


Tim Dick, Chief Financial Officer, +1-847-279-6150

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.